m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00670)
Name
3-Pyridin-3-yl-quinoline-6,7-diol
Status
Investigative
Structure
Formula
C14H10N2O2
InChI
1S/C14H10N2O2/c17-13-5-10-4-11(9-2-1-3-15-7-9)8-16-12(10)6-14(13)18/h1-8,17-18H
InChIKey
QQQXEUOUDIWAIJ-UHFFFAOYSA-N
PubChem CID
135453851
TTD Drug ID
D0IR5I
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Platelet-derived growth factor receptor alpha (PDGFRA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Pyridin-3-yl-quinoline-6,7-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-3-yl-quinoline-6,7-diol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). [1], [2]
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for 3-Pyridin-3-yl-quinoline-6,7-diol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 3-Pyridin-3-yl-quinoline-6,7-diol through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). [2], [3]
References
Ref 1 METTL3-mediated N (6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022 Jan 1;12(1):277-289. doi: 10.7150/thno.63441. eCollection 2022.
Ref 2 A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. doi: 10.1021/jm00040a003.
Ref 3 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.